trending Market Intelligence /marketintelligence/en/news-insights/trending/ymafn6ieuovumwmxyrwkkq2 content esgSubNav
In This List

Pfizer skin disease drug bags US FDA breakthrough therapy designation

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity

Blog

Insight Weekly: Bank mergers of equals return; energy tops S&P 500; green bond sales to rise

Blog

Insight Weekly: US companies boost liquidity; auto insurers hike rates; office sector risk rises


Pfizer skin disease drug bags US FDA breakthrough therapy designation

Pfizer Inc. received the U.S. Food and Drug Administration's breakthrough therapy designation for PF-04965842 to treat a skin disease.

The drug is being developed as a treatment of moderate to severe atopic dermatitis, a chronic inflammatory disease that makes the skin red and itchy.

The designation will help expedite development and review of the drug which targets the Janus kinase, or JAK, family of enzymes in the body.

The U.S. regulator previously awarded the same designation to AbbVie Inc.'s ABT-494, or upadacitinib, another JAK inhibitor being investigated as a treatment for moderate to severe atopic dermatitis.